Orthocell (ASX:OCC) signed up Device Technologies Asia as its exclusive distributor for nerve repair damage device Remplir for the Singaporean market, according to a Wednesday filing with the Australian bourse.
First sales from the new market are anticipated in the first quarter of 2025, the filing said.
Device Technologies is currently the distributor of Remplir in Australia and New Zealand, as per the filing.
The company's shares surged nearly 19% in recent Wednesday trade and earlier hit a new 52-week high.
Price (AUD): $0.76, Change: $+0.12, Percent Change: +18.75%
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。